Literature DB >> 12813445

Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants.

Andrew Daly1, Steven McAfee, Bimal Dey, Christine Colby, Leah Schulte, Beow Yeap, Robert Sackstein, Nancy J Tarbell, David Sachs, Megan Sykes, Thomas R Spitzer.   

Abstract

Infections are a common complication of allogeneic bone marrow transplantation and the leading cause of transplantation-related mortality. It had been hypothesized that transplantation following nonmyeloablative preparative regimens would result in fewer infections by causing less mucosal injury, less graft-versus-host disease, and allowing earlier immune reconstitution. We have retrospectively reviewed the infectious complications of 65 consecutive patients with advanced hematologic malignancies who underwent bone marrow transplantation using a novel preparative regimen consisting of cyclophosphamide, thymic irradiation, and in vivo T-cell depletion. Cytomegalovirus (CMV) infection occurred in 52% of cases in which the donor or recipient had evidence of prior CMV exposure. Using a strategy of preemptive therapy and secondary prophylaxis with ganciclovir, no CMV disease occurred. Infections with gram-positive bacteria predominated over the first 100 days after bone marrow transplantation. Thereafter, the relative proportion of gram-negative infections increased without a significant increase in episodes of neutropenia. The rate of bacterial infections was not influenced by relapse of the underlying malignancy. Seven patients developed infections with Aspergillus species, which was the most common infectious cause of death in these patients. Infections with viruses other than CMV (n=10) and with protozoan organisms (n=2) also occurred. The use of HLA-mismatched donors, the occurrence of grade II-IV acute graft-versus-host disease, and treatment with corticosteroids did not influence the risk of CMV or bacterial or fungal infections in patients who underwent transplantation following this preparative regimen. Overall, the incidence and spectrum of infections in this series was similar to the reported incidence of infections following conventional myeloablative allogeneic stem cell transplantation. We conclude that a quantitative T-cell deficiency in these extensively T-cell depleted patients may be a risk factor for infection, even in the absence of graft-versus-host disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12813445     DOI: 10.1016/s1083-8791(03)00100-9

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  16 in total

1.  Induction of transplantation tolerance to fully mismatched cardiac allografts by T cell mediated delivery of alloantigen.

Authors:  Chaorui Tian; Xueli Yuan; Peter T Jindra; Jessamyn Bagley; Mohamed H Sayegh; John Iacomini
Journal:  Clin Immunol       Date:  2010-05-08       Impact factor: 3.969

2.  Monocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation.

Authors:  Ursula Hainz; Petra Obexer; Christiana Winkler; Peter Sedlmayr; Osamu Takikawa; Hildegard Greinix; Anita Lawitschka; Ulrike Pötschger; Dietmar Fuchs; Stephan Ladisch; Andreas Heitger
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

3.  Nonmyeloablative conditioning with busulfan before matched littermate bone marrow transplantation results in reversal of the disease phenotype in canine leukocyte adhesion deficiency.

Authors:  Robert A Sokolic; Thomas R Bauer; Yu-Chen Gu; Mehreen Hai; Laura M Tuschong; Tanya Burkholder; Lyn Colenda; John Bacher; Matthew F Starost; Dennis D Hickstein
Journal:  Biol Blood Marrow Transplant       Date:  2005-10       Impact factor: 5.742

4.  Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow/kidney transplantation.

Authors:  G Andreola; M Chittenden; J Shaffer; A B Cosimi; T Kawai; P Cotter; S A Locascio; T Morokata; B R Dey; N T Tolkoff-Rubin; F Preffer; T Bonnefoix; K Kattleman; T R Spitzer; D H Sachs; M Sykes
Journal:  Am J Transplant       Date:  2011-06       Impact factor: 8.086

Review 5.  Cellular immune therapy for refractory cancers: novel therapeutic strategies.

Authors:  Karen K Ballen; Gerald Colvin; Bimalangshu R Dey; David Porter; Peter Westervelt; Thomas R Spitzer; Peter J Quesenberry
Journal:  Exp Hematol       Date:  2005-12       Impact factor: 3.084

Review 6.  Low dose total body irradiation followed by allogeneic lymphocyte infusion for refractory hematologic malignancy--an updated review.

Authors:  Karen K Ballen; Gerald Colvin; David Porter; Peter J Quesenberry
Journal:  Leuk Lymphoma       Date:  2004-05

7.  Induction of transplantation tolerance by combining non-myeloablative conditioning with delivery of alloantigen by T cells.

Authors:  Chaorui Tian; Xueli Yuan; Jessamyn Bagley; Bruce R Blazar; Mohamed H Sayegh; John Iacomini
Journal:  Clin Immunol       Date:  2008-02-15       Impact factor: 3.969

8.  High-throughput screening identifies two classes of antibiotics as radioprotectors: tetracyclines and fluoroquinolones.

Authors:  Kwanghee Kim; Julianne M Pollard; Andrew J Norris; J Tyson McDonald; Yingli Sun; Ewa Micewicz; Kelly Pettijohn; Robert Damoiseaux; Keisuke S Iwamoto; James W Sayre; Brendan D Price; Richard A Gatti; William H McBride
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

9.  A characterization of the oral microbiome in allogeneic stem cell transplant patients.

Authors:  Nancy J Ames; Pawel Sulima; Thoi Ngo; Jennifer Barb; Peter J Munson; Bruce J Paster; Thomas C Hart
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

10.  Tolerance to MHC class II disparate allografts through genetic modification of bone marrow.

Authors:  P T Jindra; S Tripathi; C Tian; J Iacomini; J Bagley
Journal:  Gene Ther       Date:  2012-07-26       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.